| 발표일자: |
2015년 11월 6일(금) ~ 11월 8일(일) |
| 발표번호: |
P(e-poster)-103 |
| 발표장소: |
킨텍스 제2전시장 7B홀 |
|
|
| 삼출성 나이관련황반변성에서 유리체강내 라니비주맙과 애플리버셉트 주입술의 효과 비교 |
| 한길안과병원 |
| 정희영, 이정현, 이경민, 박영숙, 손준홍, 황덕진 |
|
목적 : To compare the effectiveness of three consecutive intravitreal injections of ranibizumab (Lucentis) and aflibercept (Eylea) in patients with treatment naïve neovascular age-related macular degeneration (nAMD).
방법 : In this comparative study, 58 patients with nAMD were treated with at least 3 consecutive monthly injections of ranibizumab (0.5 mg/0.05 mL) or aflibercept (2 mg/0.05 mL) between June 2014 and April 2015 as determined by physician and patient preference. Ophthalmic evaluations included monthly visual acuity measurements, central macular thickness (CMT) and subfoveal choroidal thickness (CT) by optical coherence tomography imaging at each visit.
결과 : BCVA changes in both groups were significantly improved after 3 consecutive monthly injections. CMT significantly decreased over time, but CT was unchanged throughout the study in all groups. At each time point, the change of corrective visual acuity, CMT, and CT was not significantly different in aflibercept-treated eyes compared with ranibizumab-treated eyes. Ocular and systemic adverse events were no found in both groups.
결론 : Intravitreal aflibercept and ranibizumab produced similar efficacy and safety outcomes. These studies demonstrate that aflibercept and ranibizumab are effective for the reduction of CMT, but not effective for the reduction of CT of nAMD.
|
| |